Estrella Immunopharma, Inc.
ESLADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How ESLA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB103 | Phase 2 | B-Cell Non-Hodgkin's Lymphoma (NHL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Estrella Immunopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Estrella Immunopharma, Inc.'s (ESLA) pipeline across Phase 2. Its lead program is EB103 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Estrella Immunopharma, Inc.'s next FDA catalyst?→
Estrella Immunopharma, Inc.'s (ESLA) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ESLA biotech catalysts?→
Add ESLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Estrella Immunopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.